Precision Biosearch

Precision BioSearch secures, ‘VP, Head of Drug Discovery and Preclinical Development’ for an entrepreneur-backed drug development company

Precision BioSearch partnered with Pangea Botanica, the latest venture from a team with a track record of building companies around nature-inspired compounds and biotech platforms, such as COMPASS Pathways and ATAI Life Sciences, both unicorn companies that listed on the NASDAQ stock exchange. Precision BioSearch was pleased to secure the appointment of Dr Alleyn Plowright as, ‘VP, Head of Drug Discovery and Preclinical Development’.


Alleyn is a seasoned drug discovery leader, with 20+ years’ experience across a range of therapeutic areas, leading multi-disciplinary teams in AstraZeneca, Sanofi, and most recently as Head of Translational Science and Preclinical Development at Wren Therapeutics. He and his teams have contributed to the delivery of a range of compounds to the clinic, including three currently in Phase 2 clinical trials. 


Alleyn completed his PhD at the University of Nottingham, and postdoctoral studies at Harvard University. He has authored more than 70 publications and patents.


Commenting on the partnership, Lars Wilde, CEO & Founder at Pangea Botanica, said:

“We were delighted to partner with Precision BioSearch on our recent appointment of Alleyn Plowright.  Alleyn is a seasoned drug discovery leader, and we are delighted to have had a successful search working with Malcolm and Jemma.”


About Pangea Botanica: Pangea Botanica is a platform company focusing on the discovery and development of small molecule therapeutics for unmet patient needs, which are inspired by naturally occurring compounds and traditional remedies. 


With a core focus on nature-inspired compounds with prior evidence of safety and efficacy, Pangea Botanica has a higher likelihood of success and significantly reduced timelines in developing new medicines for patients. 


Their portfolio already comprises four drug development programs targeting auto-immune, psychiatric, neurodegenerative and neurological indications, complemented by a proprietary AI-driven discovery engine.


For more information, visit:




Posted on : 25th January 2023